Newswise — The FDA will decide on flibanserin, a pharmacological option for female sexual dysfunction, on or before Aug. 18. Sheryl Kingsberg, PhD, Chief of Behavioral Medicine at University Hospitals Case Medical Center, testified before an advisory committee and calls it a double standard that men have more than two dozen options for sexual problems while women have zero.